Remus Pharmaceuticals Ltd Q2 FY26 Earnings Analysis
Published 8 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹906 Cr
Price
₹879
Market Cap
₹906 Cr
P/E Ratio
24.5
Revenue Rank
Margin Rank
How does Remus Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Remus Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Earnings Summary
US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions. Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business.
📊 Revenue & Sales Performance
Rank 2- →US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions.
- →Both US subsidiary and standalone/emerging market businesses expected to grow proportionately, maintaining or slightly adjusting revenue shares.
- →Emerging market revenues currently ~20%; management anticipates this to increase to 25-30% over time as B2C segment grows rapidly.
- →B2C business increased from 4% to 13% of revenues in H1 FY26; targeted to reach 18-20% by end-FY26 and 20-25% within next 1.5 years.
- →Overall revenue growth supported by expansion into new geographies including Algeria, Kenya, Chile, Dominican Republic, and African markets.
- →High-margin emerging markets and B2C growth expected to improve blended PAT margins from current ~5% towards 8-10% in near future.
- →Management focused on expanding niche, high-value products, and building direct brand presence for sustained volume and value growth.
📈 Profitability & Margins
Rank 1- →Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business.
- →B2C revenue contribution grew from 4% to 13% in H1 FY26, with a target to reach around 18-20% by the end of the financial year and 20-25% within the next 1.5 years.
- →EBITDA margins for B2C are around 35%, significantly higher than the current overall EBITDA margin of about 7%.
- →Consolidated PAT margin currently at ~5%, with management aiming to improve it to 8-10% over the next 1-2 years.
- →US subsidiary, which contributes ~80% of revenue, is stable with gradual growth expected; emerging markets to gain higher revenue share over time.
- →Positive outlook on PAT growth driven by increasing B2C share, new subsidiaries, and operational efficiencies.
- →Management indicates a steady growth trajectory without specific numeric guidance but expects continued strong earnings momentum.
🏗️ Capital Expenditure Plans
Yes- →Remus Pharmaceuticals is actively expanding its international footprint, including recent entry into Algeria and plans for subsidiary establishments in new countries such as Kenya, Chile, and Dominican Republic.
- →The company is focusing on building its B2C segment, including launching new products like Rivastigmine patches and other dermal patches, indicating investment in product development.
- →They are setting up a new subsidiary for clinical trials and research services, which will contribute to future operational growth.
- →Investments in technology transfer and licensing deals with local manufacturers (e.g., Algeria) are part of strategic efforts to enhance manufacturing collaborations and royalties.
- →The approach includes strong due diligence and market visits before entering new countries, signaling strategic capital allocation for market expansion.
- →While exact capex figures or timelines are not disclosed, they aim to grow B2C contributions from 13% to around 20-25% of revenues, implying ongoing investment in building brand presence and infrastructure.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q2 FY26 results?
US business currently contributes ~80% of consolidated revenues; H1 FY25 to H1 FY26 saw ~40% growth in US standalone revenues due to new market entries and customer acquisitions. Remus Pharmaceuticals expects growth in both B2B and B2C segments, with a strong focus on expanding the higher-margin B2C business.
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 24.5 with a market cap of ₹906 Cr. Investors should review the full earnings analysis for detailed insights.
Is Remus Pharmaceuticals Ltd planning capital expenditure?
Remus Pharmaceuticals is actively expanding its international footprint, including recent entry into Algeria and plans for subsidiary establishments in new countries such as Kenya, Chile, and Dominican Republic.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.